Venture Life Sells Non-Core Oral Care Assets to Focus on Core Brands

Venture Life ( (GB:VLG) ) has shared an announcement.

Venture Life Group PLC has completed the sale of its non-core Oral Care Assets, including Ultradex and Dentyl brands, to Covestus Holdings Ltd for up to £4.5 million. This divestment aligns with Venture Life’s strategic focus on its higher margin, higher growth core brands, and the proceeds will be used to bolster its acquisition strategy and drive innovation in its core product categories. The sale also allows the company to streamline operations and focus on its Power Brands, promoting proactive healthy longevity for consumers.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Spark’s Take on GB:VLG Stock

According to Spark, TipRanks’ AI Analyst, GB:VLG is a Neutral.

Venture Life’s stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.

To see Spark’s full report on GB:VLG stock, click here.

More about Venture Life

Venture Life is an international consumer self-care company focused on commercializing products for the global self-care market. Headquartered in the UK, its product portfolio includes Balance Activ for women’s intimate healthcare, Earol for ENT care, Lift and Glucogel for energy and glucose management, and the Health and Her product range supporting the hormonal lifecycle. The company’s products are primarily available through pharmacies and grocery multiples and are sold in over 90 countries worldwide.

Average Trading Volume: 170,208

Technical Sentiment Signal: Buy

Current Market Cap: £78.47M

See more insights into VLG stock on TipRanks’ Stock Analysis page.